Seven ways to preserve the Miracle of antibiotics

Clinical Infectious Diseases

Volumn 56, Issue 10, 2013, Pages 1445-1450

  Bartlett, John G ^a   Gilbert, David N ^b   Spellberg, Brad ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c Liu Vaccine Center   (United States)

Author keywords

antibiotic resistance; antibiotic salvage; European Union, stewardship; molecular diagnostics

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL DECISION MAKING; DRUG ABUSE; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG USE; FARM ANIMAL; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HOSPITAL INFECTION; HOSPITAL MANAGEMENT; HUMAN; INTENSIVE CARE UNIT; MEDICAL ERROR; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED STATES; VIRUS INFECTION;

ANIMALS; ANIMALS, DOMESTIC; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; EUROPEAN UNION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; SALVAGE THERAPY; UNITED STATES;

EID: 84877294743     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit070     Document Type: Review

References (40)

1. Fleming A. Penicillin's finder assays its future. New York Times 1945; 21.
2. The evolving threat of antimicrobial resistance: options for action. Geneva, Switzerland: World Health Organization, 2012. ISBN: 9789241503181.
3. Infectious Diseases Society of America. The 10×20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50:1081.
4. US Food and Drug Administration. 2010 summary report on antimicrobials sold or distributed for use in food producing animals, 2011. Available at: http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/ M277657.pdf. Accessed 17 February 2012.
5. Hamad B. The antibiotics market. Nat Rev Drug Discov 2010; 9:675.
6. Sharma P, Towse A. New drugs to tackle antimicrobial resistance: analysis of EU policy options. London: Office of Health Economics. Available at: http://www.ohe./org/publications/article/new-drugs-totackle-2012 resistance-5.cfm. Accessed 5 July 2012.
7. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52(suppl 4):S296-304.
8. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202-9.
9. Centers for Disease Control and Prevention . Vital signs: central line-associated blood stream infections-United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 2011; 60:243-8.
10. Scanfeld D, Scanfeld V, Larson EL. Dissemination of health information through social networks: Twitter and antibiotics. Am J Infect Control 2010; 38:182-8.
11. Watson R. Europe launches 12 point plan to tackle antimicrobial resistance. BMJ 2011; 343:d7528.
12. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 209:2588-98.
13. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days for women with acute pyelonephritis: a randomized, open-label and double blind placebo controlled, non-inferiority trial. Lancet 2012; 380:484.
14. Peltola H, Pääkkönen M, Kallio MJ, Osteomyelitis-Septic Arthritis Study Group. Short-versus long term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases. Pediatr Infect Dis J 2010; 29:1123-8.
15. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double blind study. BMJ 2006; 332:1355.
16. van Cleef B, Kluytmans J, Bentheu B, et al. Cross border comparison of MRSA bacteremia between the Netherlands and North Rhine-Westphalia (Germany): a cross sectional study. PloS One 2012; 7: e42787.
17. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitoninguided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009; 37:497-507.
18. Ansari F, Molana H, Goossens H, Davey P. ESAC II Hospital Care Study Group. Development of standardized methods for analysis of changes in antibacterial use in hospitals from 18 European countries: the European Surveillance of Antimicrobial Consumption (ESAC) longitudinal survey, 2000-06. J Antimicrob Chemother 2010; 65:2685-91.
19. National Institute for Public Health and the Environment, Ministry of Health, Welfare and Sport. NETHMAP 2011: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. SWAB. Available at: http://www.swab/cms3.nsf/uploads/35ACD 3A546C31716c12578BF002EDC/$FILE/NethMap2011.pdf. Accessed 4 September 2012.
20. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis 2011; 53:177.
21. Sabuncu E, David J, Bernede-Bauduin C, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-07. PLoS Med 2009; 6:e1000084.
22. Marshall BM, Levy S. Food animals and antibiotics: impacts on human health. Clin Microbid Rev 2011; 24:718-33.
23. Aarestrup FM, Jensen VF, Emborg HD, Jacobsen E, Wegener HC. Changes in the use of antimicrobials and the effects on productivity of swine farms in Denmark. Am J Vet Res 2010; 71:726-33.
24. Wright GD. Antibiotic resistance in the environment: a link to the clinic. Curr Opin Microbiol 2010; 13:589-94.
25. Pronovost P, Needham D, Berenholtz S. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725-32.
26. Waters HR, Korn R Jr, Colantuoni E, et al. The business cases for quality economic analysis of the Michigan Keystone Patient Safety Program in ICUs. Am J Med Qual 2011; 26:333-9.
27. Srinivasan A, Craig M, Cardo D. The power of policy change, federal collaboration, and state coordination in healthcare-associated infection prevention. Clin Infect Dis 2012; 55:426-31.
28. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49:1175-84.
29. Arnold HM, Micek ST, Skrupky LP, Koleff MH. Antibiotic stewardship in the intensive care unit. Semin Respir Crit Care Med 2011; 12:2062-9.
30. Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole gene sequencing. Sci Transl Med 2012; 4:1-9.
31. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007; 45(suppl 1):S89-95.
32. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 2011; 11:464-9.
33. Arnold SR, Strauss SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005; 19: CD003539.
34. Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011; 52(suppl 4): S326-30.
35. Jeng K, Massire C, Zembower TR, et al. Monitoring seasonal influenza A evolution: rapid 2009 pandemic H1N1 surveillance with an reverse transcription-polymerase chain reaction/electro-spray ionization mass spectrometry assay. J Clin Virol 2012; 54:332-6.
36. Al Masalma M, Armougom F, Scheld WM, et al. The expansion of the microbiological spectrum of brain abscesses with use of multiple 16S ribosomal DNA sequencing. Clin Infect Dis 2009; 48:1169-78.
37. Promoting Anti-Infective Development and Antimicrobial Stewardship through the US Food and Drug Administration Prescription Drug User Fee Act (PDUFA). Reauthorization: Before the House Committee on Energy and Commerce's Subcommittee on Health 2012. Available at: http://www.idsociety.org/ uploadedFiles/IDSA/Policy-and-Advocacy/Current topics-and-Issues/Advancing- Product-Research-and-Development/Bad-BugsNo-Drugs/Statements/IDSA%20PDUFA% 20GAIN%20Testimony%20030812%20FINAL.pdf. Accessed 13 September 2012.
38. Spellberg B, Sharma P, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov 2012; 11:168.
39. Sebelius K. Building a stronger foundation for a new century of treatments and cures. Health Aff (Millwood) 2011; 30:81-3.
40. Dolgin E. Trial networks move beyond single-disease strategies. Nat Med 2011; 17:1525.